There are currently 74 active clinical trials seeking participants for Metastatic Cancer research studies. The states with the highest number of trials for Autism participants are California, Ohio, Michigan and Illinois.
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
NCT05840510
Recruiting
This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC with a KRAS G12C mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/02/2024
Locations: Research Site, Cleveland, Ohio +2 locations
Conditions: Solid Tumor, Adult, NSCLC, Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Register for Updates
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
NCT05065736
Recruiting
The purpose of this study is to evaluate whether a new type of imaging study, called 18F-Clofarabine (CFA) PET/CT, can be used to image cancer pyrimidine metabolism in participants. PET (positron emission tomography) imaging is a way of looking at cancers that can reveal cancer metabolism. Presently, however, there are no imaging agents in routine use to look at an aspect of cancer metabolism (pyrimidine metabolism) that dictates whether certain cancer drugs, e.g., gemcitabine, are likely to be... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/05/2024
Locations: Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Metastatic Cancer, Carcinoma, Adenocarcinoma
Register for Updates
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
NCT05864144
Recruiting
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Sanford Cancer Center, Sioux Falls, South Dakota +3 locations
Conditions: Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer
Register for Updates
UNC Metastatic Cancer Radiation Therapy Registry
NCT06306924
Recruiting
The purpose of this registry is to collect clinical data from participants attending UNC Hospitals who present with metastatic cancer and are evaluated to receive radiation therapy as part of their standard of care treatment. The goal of this study is to provide a foundation for studies designed to identify projects across the translational continuum related to metastatic cancer and radiation therapy treatment. The relevant clinical data will be linked to patient-reported outcomes (PROs) thus al... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill, North Carolina
Conditions: Cancer, Metastatic Cancer
Register for Updates
Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy
NCT05831579
Recruiting
Spatially fractionated radiotherapy (SFRT or GRID) addresses some limitations of traditional stereotactic body radiation therapy by relying on beam collimation to create high-dose "peaks" and intervening low-dose "valleys" throughout the target volume. Standard palliative radiotherapy regimens provide limited durability of response, and there are challenges with delivery to large tumors or in previously irradiated fields. In this study, Proton GRID radiotherapy will be used to deliver three-frac... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Unresectable Solid Tumor, Metastatic Cancer
Register for Updates
Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas
NCT06389123
Recruiting
This is a Phase I study to evaluate the safety and efficacy of the [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G theranostics pair in patients with metastatic cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: The University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Metastatic Cancer
Register for Updates
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
NCT05678010
Recruiting
The purpose of this study is to find out whether AZD1390 combined with stereotactic body radiation therapy/SBRT is a safe treatment for people with metastatic solid tumor cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey +4 locations
Conditions: Solid Tumor, Metastatic Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Tumor, Metastatic Cancer
Register for Updates
Biomarkers to Detect Endocrine Therapy Resistance
NCT06067503
Recruiting
This pilot observational study is being done to identify possible biomarkers of response to endocrine therapy in patients with ER/PR+ metastatic lobular breast cancer (LBC) starting new endocrine therapy. 18F-fluorofuranylnorprogesterone Positron Emission Tomography/Computed Tomography (FFNP-PET/CT) and liquid biopsies will be performed at baseline and after 4 weeks of treatment. Baseline levels and dynamic on-treatment changes in estrogen signaling as measured by FFNP-PET/CT and circulating tum... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: UW Carbone Cancer Center, Madison, Wisconsin
Conditions: Metastatic Cancer, Breast Cancer, Lobular Breast Carcinoma
Register for Updates
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
NCT05557045
Recruiting
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: SCRI HealthOne, Denver, Colorado +6 locations
Conditions: Advanced Cancer, Metastatic Cancer, Solid Tumor
Register for Updates
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
NCT04090528
Recruiting
This trial will evaluate the use of one versus two DNA vaccines, delivered concurrently with PD-1 blockade using pembrolizumab followed by treatment with pembrolizumab alone, and delivered over a prolonged period of time (for a maximum of 2 years (32 cycles) or until radiographic progression) on the treatment of castrate-resistant, metastatic prostate cancer. The hypothesis to be tested is that delivering two vaccines with PD-1 blockade will elicit a greater frequency and magnitude of tumor-dire... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Washington University Siteman Cancer Center, Saint Louis, Missouri +1 locations
Conditions: Castration-resistant Prostate Cancer, Metastatic Cancer, Prostate Cancer
Register for Updates
Randomized Clinical Trial of a Multi-Modal Palliative Care Intervention
NCT04773639
Recruiting
Adults diagnosed with metastatic cancer commonly experience depression and anxiety symptoms, which can interfere with advance care planning. This randomized clinical trial evaluates a novel, piloted, primary palliative care intervention that addresses advance care planning and psychosocial needs of patients with metastatic cancer. The intervention focuses on patients with elevated anxiety and depression (anx/dep) symptoms-those with highest psychosocial needs who may be at greatest risk for adva... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/10/2024
Locations: Rocky Mountain Cancer Centers, Boulder, Colorado
Conditions: Depression, Anxiety, Metastatic Cancer
Register for Updates
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249
Recruiting
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +97 locations
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Register for Updates